Luxcel Biosciences Ltd announce world's first physiologically relevant, in vitro Ischemia-Reperfusion Model in conjunction with BMG LABTECH and Ncardia.
Ischemia-reperfusion (IR) injury, occurs in the body when blood supply returns to tissues after a period of oxygen and nutrient deprivation. It is an important feature of several diseases including cardiac arrest, stroke and cancer, and is a critical consideration during transplantation. While significant advances have been made in understanding IR injury, progress has been impaired by i. the absence of a method to accurately and reproducibly replicate injury conditions in vitro, and ii. tools have not been available to quantitatively measure real-time cellular oxygenation in the ischemic cells.
These barriers to better understanding and treating IR injury have now been overcome, with the groundbreaking development of the first microplate-based in vitro Ischemia-Reperfusion Model. This advance is made possible by combining three innovative new technologies: i. BMG LABTECH’s CLARIOstar® microtitre plate reader, with Atmoshpheric Control Unit (ACU) and rapid gas ramping function, ii. Luxcel Biosciences’ unique MitoXpress® Intra – Intracellular Oxygen Concentration Assay, allowing real-time quantitation of cellular oxygenation, and iii. Ncardia’s iPSC-derived human Cor.4U® cardiomyocyte cells. This powerful new in vitro model will enable researchers and drug discovery scientists to better replicate and understand the biology of IR injury facilitating the development of more effective therapeutic interventions.
“We are really excited about this innovative new tool for the ischemia reperfusion field, made possible by our recently reported MetaCell-TM collaboration, supported by the EU H2020 fast track to innovation initiative. The CLARIOstar® has integrated software for the MitoXpress® Intra assay, allowing scientists to consistently and accurately quantify the oxygen concentration within the cells as they experience rapid deand re-oxygenation, and see this happening in real-time. We believe this model has the potential to revolutionise the approach researchers in cell biology and drug safety toxicity can take to evaluate ischemic reperfusion and to reduce the dependency for in vivo animal models.” Dr. Ian Hayes, Commercial Director Luxcel Biosciences Ltd.